Genentech releases Lunsumio data in earlier treatment lines for lymphomas

 – Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of Phase III CELESTIMO study –

– Data from subcutaneous Lunsumio plus Polivy reinforce its outpatient, chemotherapy-free potential in people with R/R large B-cell lymphoma –

– Results highlight the potential of innovative Lunsumio combination regimens to offer improved outcomes for more people with lymphoma earlier in their disease –

https://www.businesswire.com/news/home/20251208047623/en/Genentech-Presents-Lunsumio-Data-Showing-Potential-Across-Earlier-Treatment-Lines-in-Indolent-and-Aggressive-Lymphomas